MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Edwards Lifesciences Corporation Book Value 2011-2026 | EW
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.3 B | 10.1 B | 6.72 B | 5.81 B | 5.84 B | 4.57 B | 4.15 B | 3.14 B | 2.96 B | 2.62 B | 2.5 B | 2.19 B | 1.56 B | 1.48 B | 1.34 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.3 B | 1.34 B | 4.35 B |
Quarterly Book Value Edwards Lifesciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 B | 10.6 B | 10.2 B | 10.1 B | 9.61 B | 7.5 B | 7.19 B | 6.72 B | 6.73 B | 6.45 B | 6.06 B | 5.81 B | 6.22 B | - | 5.84 B | 5.84 B | 5.54 B | 7.66 B | 7.21 B | 4.57 B | 4.57 B | 7.24 B | 7.24 B | 6.49 B | 6.49 B | 6.49 B | 6.49 B | 5.32 B | 5.32 B | 5.32 B | 5.32 B | 5.67 B | 5.67 B | 5.67 B | 5.65 B | 4.51 B | 4.51 B | 4.51 B | 4.51 B | 4.06 B | 4.06 B | 4.06 B | 4.06 B | 3.52 B | 3.52 B | 3.52 B | 3.52 B | 2.71 B | 2.71 B | 2.71 B | 2.71 B | 2.22 B | 2.22 B | 2.22 B | 2.22 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.6 B | 1.98 B | 5.26 B |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | USA |
 |
Beyond Air
XAIR
|
14.3 M | $ 0.72 | 3.86 % | $ 48.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | USA |
 |
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M |  China |
 |
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | USA |
 |
Xtant Medical Holdings
XTNT
|
43 M | $ 0.54 | -4.43 % | $ 72.2 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
12.5 B | $ 88.29 | -0.97 % | $ 17.9 B | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Align Technology
ALGN
|
3.85 B | $ 165.93 | -6.43 % | $ 12.4 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | USA |
 |
Alphatec Holdings
ATEC
|
791 M | $ 10.9 | -5.43 % | $ 1.64 B | USA |
 |
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | USA |
 |
Accuray Incorporated
ARAY
|
81.2 M | $ 0.39 | 4.51 % | $ 40.1 M | USA |
 |
Abbott Laboratories
ABT
|
86.7 B | $ 104.33 | -0.23 % | $ 182 B | USA |
 |
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 69.42 | -1.07 % | $ 103 B | USA |
 |
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | USA |
 |
CONMED Corporation
CNMD
|
1.03 B | $ 34.68 | -5.35 % | $ 1.08 B | USA |
 |
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
NanoVibronix
NAOV
|
627 K | - | - | $ 1.08 M | USA |
 |
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11.1 M | $ 0.6 | -0.18 % | $ 32.7 M | USA |
 |
Aethlon Medical
AEMD
|
5.12 M | $ 2.14 | -5.73 % | $ 3.34 M | USA |
 |
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
1.53 B | $ 11.11 | -2.63 % | $ 1.5 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.65 | -4.31 % | $ 367 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
9.26 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
11.4 M | $ 0.67 | -1.26 % | $ 28 M | USA |
 |
Penumbra
PEN
|
1.43 B | $ 335.28 | -0.34 % | $ 13 B | USA |
 |
Inspire Medical Systems
INSP
|
781 M | $ 49.77 | -1.35 % | $ 1.46 B | USA |
 |
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |
 |
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
101 M | - | - | $ 10.2 M | USA |
 |
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
231 M | - | - | $ 217 M | USA |
 |
Surgalign Holdings
SRGA
|
-15.7 M | - | -32.98 % | $ 1.68 M | USA |
 |
STRATA Skin Sciences
SSKN
|
21.8 M | - | - | $ 6.6 M | USA |